share_log

藥明康德:海外監管公告

WUXI APPTEC: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Mar 26 05:31
Summary by Moomoo AI
药明康德於2024年3月27日發布公告,提醒其2019年限制性股票與股票期權激勵計劃下首次授予的股票期權進入第三個行權期,該行權期自2023年6月27日開始至2024年5月25日結束。公司指出,目前正處於自主行權階段,但將於2024年4月1日至4月29日進入限制行權期間,在此期間所有激勵對象將無法行使股票期權。药明康德董事會確保公告內容的真實性、準確性和完整性,並承擔相應的法律責任。
药明康德於2024年3月27日發布公告,提醒其2019年限制性股票與股票期權激勵計劃下首次授予的股票期權進入第三個行權期,該行權期自2023年6月27日開始至2024年5月25日結束。公司指出,目前正處於自主行權階段,但將於2024年4月1日至4月29日進入限制行權期間,在此期間所有激勵對象將無法行使股票期權。药明康德董事會確保公告內容的真實性、準確性和完整性,並承擔相應的法律責任。
Ming Kand Pharmaceuticals issued a notice on March 27, 2024 reminding that the stock options first granted under its 2019 Restrictive Stock and Stock Option Incentive Program will enter into the third line option, which will run from June 27, 2023 to May 25, 2024. The Company noted that it is currently in the autonomy phase, but will enter a restricted exercise period from April 1 to April 29, 2024, during which all inductees will not be able to exercise stock options. The Board of Directors of Ming Kand Pharmaceuticals ensures the truthfulness, accuracy and completeness of the contents of the announcement and assumes its legal responsibilities accordingly.
Ming Kand Pharmaceuticals issued a notice on March 27, 2024 reminding that the stock options first granted under its 2019 Restrictive Stock and Stock Option Incentive Program will enter into the third line option, which will run from June 27, 2023 to May 25, 2024. The Company noted that it is currently in the autonomy phase, but will enter a restricted exercise period from April 1 to April 29, 2024, during which all inductees will not be able to exercise stock options. The Board of Directors of Ming Kand Pharmaceuticals ensures the truthfulness, accuracy and completeness of the contents of the announcement and assumes its legal responsibilities accordingly.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more